Immunotherapy on acid: opportunities and challenges

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Effect of hypoxia and acidosis on immune function.

References

  1. 1.

    Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2017;36:439–45. https://doi.org/10.1038/onc.2016.225.

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Lazarus D, Peters C, Stockmann A, Eliasof S, Jayaraman L. Abstract 3209: CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models. Cancer Res. 2016;76:3209.

    Google Scholar 

  3. 3.

    McDonald PC, Chafe SC, Dedhar S. Overcoming hypoxia-mediated tumor progression: combinatorial approaches targeting pH regulation, angiogenesis and immune dysfunction. Front Cell Dev Biol. 2016;4:27.

    Article  Google Scholar 

  4. 4.

    Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol. 2001;69:522–30.

    PubMed  CAS  Google Scholar 

  5. 5.

    El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, et al. Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Br J Cancer. 2019;121:556–66.

    Article  CAS  Google Scholar 

  6. 6.

    Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9:674–87. https://doi.org/10.1038/nrclinonc.2012.171.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. J Nucl Med. 2010;51:1167–70. https://doi.org/10.2967/jnumed.109.068981.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. 8.

    Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393–410. https://doi.org/10.1038/nrc3064.

    Article  PubMed  CAS  Google Scholar 

  9. 9.

    Lindner LH. Hypoxia-activated prodrug: an appealing preclinical concept yet lost in clinical translation. Lancet Oncol. 2017;18:991–3. https://doi.org/10.1016/S1470-2045(17)30401-1.

    Article  PubMed  Google Scholar 

  10. 10.

    Jindal V. Immunotherapy: a glimmer of hope for metastatic prostate cancer. Chin Clin Oncol. 2018;7:61. https://doi.org/10.21037/cco.2018.02.01.

  11. 11.

    Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K. et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 2016;76:1381–90. https://doi.org/10.1158/0008-5472.CAN-15-1743.

    Article  PubMed  CAS  Google Scholar 

  12. 12.

    Wong WY, DeLuca CI, Tian B, Wilson I, Molund S, Warriar N, et al. Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers. J Exp Ther Oncol. 2005;5:93–99.

    PubMed  CAS  Google Scholar 

  13. 13.

    Damgaci S, Ibrahim-Hashim A, Enriquez-Navas PM, Pilon-Thomas S, Guvenis A, Gillies RJ. Hypoxia and acidosis: immune suppressors and therapeutic targets. Immunology. 2018;154:354–62.

    Article  CAS  Google Scholar 

  14. 14.

    Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Investig. 2013;123:3685–92.

    Article  CAS  Google Scholar 

Download references

Funding

This article is published as part of a supplement sponsored by NuOmix-Research k.s. The conference was financially supported by Protina Pharmazeutische GmbH, Germany and Sirius Pharma, Germany, and organized by NuOmix-Research k.s. Neither company had any role in writing of the paper.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Arig Ibrahim-Hashim.

Ethics declarations

Conflict of interest

SD and AI-H received grant support from Helix Biopharma. RJG received grant support from Helix Biopharma & Healthmyne, and NIH Small Business Innovation Research (SBIR) with Healthmyne, Inc; RJG also holds stock HealthMyne, Inc (H-M), which is a commercial quantitative PACS system for reading and analysis of radiographic scans, and held stock in Helix until 2017. SP-T received grant support from the American Cancer Society.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Damgaci, S., Enriquez-Navas, P.M., Pilon-Thomas, S. et al. Immunotherapy on acid: opportunities and challenges. Eur J Clin Nutr 74, 3–6 (2020). https://doi.org/10.1038/s41430-020-0683-7

Download citation

Search